MedMen cuts 190 jobs, sells assets as pot firms come down off an expansion high
Cash-strapped MedMen Enterprises Inc. is laying off more than 190 employees, including 20% of its corporate workforce.
The move is part of a broader corporate restructuring, with the Culver City, Calif.-based pot company targeting positive earnings before interest, taxes, depreciation and amortization by the end of 2020.
MedMen will also divest noncore assets, including the sale of its stake in Treehouse Real Estate Investment Trust for net proceeds of $14 million. MedMen created Treehouse last year, starting a trend that has seen several other pot companies spin off their real estate into separate companies.
The industry is in the midst of a “harsh and quick” transition from growth to retrenchment, MedMen Chief Executive Officer Adam Bierman said in an interview. As with many other companies in the industry, MedMen’s share price has fallen by about two-thirds since the beginning of the year, and “capital markets have been shuttered,” he said.
“We find ourselves in the exact same spot as all of the other competitors across the industry, where nobody’s fully funded because everybody’s been living in this high-growth phase,” Bierman said. “That’s why we’re taking such dramatic measures: I will not allow the company to be exposed where we didn’t act fast enough, staring down this future.”
A recent study of 30 pot firms by trade publication Marijuana Business Daily found that Los Angeles-based MedMen had the weakest cash position, with just over one month of cash coverage.
The company said Friday that it will sell its minority stakes in various brands for net proceeds of $8 million and has engaged Canaccord Genuity Corp. to “explore strategic alternatives” for operations and licenses in noncore markets. It will also limit new store openings in 2020 to those that have the potential to generate more than $10 million in revenue within the first 12 months.
The news comes one month after MedMen announced it would scrap its planned acquisition of PharmaCann LLC and terminate Chief Financial Officer Michael Kramer.
As a result of Friday’s moves, MedMen’s selling, general and administrative expense run-rate will fall to $85 million from $132 million, Bierman said.
“This is about preserving and protecting, and part of that is bolstering our balance sheet for the times ahead,” he said.
Your guide to our clean energy future
Get our Boiling Point newsletter for the latest on the power sector, water wars and more — and what they mean for California.
You may occasionally receive promotional content from the Los Angeles Times.